Adia Nutrition Inc. Appoints Dr. Evan Thomas, MD, PhD, to Drive Adia Med's Specialized Treatment Revolution
Adia Nutrition (OTCQB: ADIA) appointed Dr. Evan Thomas, MD, PhD as Independent Medical Director for its medical division, Adia Med, effective October 21, 2025. Dr. Thomas will oversee clinic practices and clinical operations, including finalizing protocols for the Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program pending in-network provider status with major insurers.
Dr. Thomas is chief medical officer at the Renaissance Institute of Precision Oncology & Radiosurgery and has expertise in CNS and functional radiosurgery, SRS/SBRT, clinical trials, and an innovative radiotherapy joint therapy called Joint Glow. The company invites clinic owners and partners to inquire about licensing and integrating Adia Med regenerative therapies.
Adia Nutrition (OTCQB: ADIA) ha nominato il Dr. Evan Thomas, MD, PhD come Direttore Medico Indipendente per la sua divisione medica, Adia Med, con effetto dal 21 ottobre 2025. Il Dott. Thomas controllerà le pratiche cliniche e le operazioni cliniche, inclusa la finalizzazione dei protocolli per il programma di Trapianto Autologo di Cellule Staminali Ematopoietiche (AHSCT) in attesa dello status di fornitore in rete presso i principali assicuratori.
Il Dott. Thomas è Chief Medical Officer presso Renaissance Institute of Precision Oncology & Radiosurgery e ha competenze in radiosurgery CNS e funzionale, SRS/SBRT, trials clinici e una joint therapy innovativa di radioterapia chiamata Joint Glow. L'azienda invita i proprietari di cliniche e i partner a informarsi su licenze e integrazione delle terapie rigenerative Adia Med.
Adia Nutrition (OTCQB: ADIA) designó al Dr. Evan Thomas, MD, PhD como Director Médico Independiente para su división médica, Adia Med, con efecto a partir del 21 de octubre de 2025. El Dr. Thomas supervisará las prácticas clínicas y las operaciones clínicas, incluida la finalización de los protocolos para el programa de Trasplante Autólogo de Médula Ósea (AHSCT) pendiente de estatus de proveedor en red con los principales aseguradores.
El Dr. Thomas es el director médico en Renaissance Institute of Precision Oncology & Radiosurgery y tiene experiencia en radiosurgery CNS y funcional, SRS/SBRT, ensayos clínicos y una innovadora terapia conjunta de radioterapia llamada Joint Glow. La empresa invita a propietarios de clínicas y socios a consultar sobre licencias e integración de las terapias regenerativas de Adia Med.
Adia Nutrition (OTCQB: ADIA)는 Dr. Evan Thomas, MD, PhD를 자회사 Adia Med의 독립 의료 이사로 2025년 10월 21일부터 임명했습니다. Thomas 박사는 임상 진료 및 임상 운영을 감독하며, 주요 보험사와의 네트워크 공급자 자격을 대기 중인 자가조혈모세포 이식(AHSCT) 프로그램의 프로토콜 완성을 포함합니다.
Thomas 박사는 Renaissance Institute of Precision Oncology & Radiosurgery의 최고 의료 책임자이며 CNS 및 기능성 방사선수술, SRS/SBRT, 임상시험 및 Joint Glow로 불리는 혁신적 방사선 치료 공동 요법에 전문성이 있습니다. 회사는 임상 소유자 및 파트너들에게 Adia Med 재생 치료의 라이선스 취득 및 통합에 관해 문의할 것을 권합니다.
Adia Nutrition (OTCQB: ADIA) a nommé le Dr. Evan Thomas, MD, PhD Directeur Médical Indépendant pour sa division médicale, Adia Med, à compter du 21 octobre 2025. Le Dr Thomas supervisera les pratiques cliniques et les opérations cliniques, y compris la finalisation des protocoles du programme de Transplantation Autologue de Cellules Souches Hématopoïétiques (AHSCT) en attente du statut de fournisseur en réseau auprès des principaux assureurs.
Le Dr Thomas est Chief Medical Officer au Renaissance Institute of Precision Oncology & Radiosurgery et possède une expertise en radiosurgie du SNC et fonctionnelle, SRS/SBRT, essais cliniques, et une thérapie radiothérapeutique conjointe innovante nommée Joint Glow. L’entreprise invite les propriétaires de cliniques et les partenaires à se renseigner sur les licences et l’intégration des thérapies régénératives d’Adia Med.
Adia Nutrition (OTCQB: ADIA) hat Dr. Evan Thomas, MD, PhD zum unabhängigen medizinischen Direktor der medizinischen Abteilung Adia Med ab dem 21. Oktober 2025 ernannt. Dr. Thomas wird die klinischen Praktiken und den klinischen Betrieb überwachen, einschließlich der Finalisierung der Protokolle für das autologe hämatopoetische Stammzelltransplantation (AHSCT)-Programm, das auf die Netzbetreiber-Status mit großen Versicherern wartet.
Dr. Thomas ist Chief Medical Officer am Renaissance Institute of Precision Oncology & Radiosurgery und verfügt über Expertise in CNS- und funktioneller Radiochirurgie, SRS/SBRT, klinischen Studien und einer innovativen Strahlentherapie-Joint-Therapy namens Joint Glow. Das Unternehmen lädt Klinikinhaber und Partner ein, sich nach Lizenzen und der Integration von Adia Med regenerativen Therapien zu erkundigen.
Adia Nutrition (OTCQB: ADIA) عَينت الدكتور إيفان توماس، MD، PhD كمدير طبي مستقل لقسمها الطبي، Adia Med، اعتباراً من 21 أكتوبر 2025. سيشرف الدكتور توماس على ممارسات العيادة وعملياتها السريرية، بما في ذلك إتمام البروتوكولات لبرنامج زرع الخلايا الجذعية المكوّنة للدم ذاتية المنشأ (AHSCT) المرتبط بالحالة كشريك مقدم الخدمات ضمن الشبكات مع شركات التأمين الكبرى.
الدكتور توماس هو المدير الطبي في Renaissance Institute of Precision Oncology & Radiosurgery ولديه خبرة في الجراحة الإشعاعية العصبية CNS والجريان الوظيفي، و SRS/SBRT، والتجارب السريرية، وفرنطيس علاجي إشعاعي مبتكر يُدعى Joint Glow. تدعو الشركة أصحاب العيادات والشركاء إلى الاستفسار عن تراخيص ودمج علاجات Adia Med التجديدية.
Adia Nutrition (OTCQB: ADIA) 任命 Evan Thomas 博士，MD，PhD 为其医疗部門 Adia Med 的独立医疗总监，自2025年10月21日起生效。Thomas 博士将负责诊所实践和临床运营，包括为拟在网络内提供者地位的主要保险公司待定的 自体造血干细胞移植（AHSCT） 项目完善方案。
Thomas 博士现任 Renaissance Institute of Precision Oncology & Radiosurgery 的首席医疗官，擅长中枢神经系统(CNS)及功能性放射治疗、SRS/SBRT、临床试验，以及一种名为 Joint Glow 的创新放射治疗联合疗法。公司邀请诊所业主与合作伙伴咨询 Adia Med 再生治疗的许可及整合事宜。
- None.
- None.
Winter Park, Florida--(Newsfile Corp. - October 21, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is excited to announce the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers.
Dr. Evan Thomas, MD, PHD
Cannot view this image? Visit:
https://images.newsfilecorp.com/files/10520/271088_image1.jpg
Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology & Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a groundbreaking therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries.
"Dr. Evan Thomas is a transformative leader who will redefine Adia Med's impact," said Larry Powalisz, CEO of Adia Nutrition Inc. "Dr. Thomas's expertise in oncology enables Adia Med to provide exceptional specialized treatments to patients and clinics across the country."
As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271088
FAQ
Who is the new medical director of Adia Nutrition (ADIA) and when was the appointment announced?
What responsibilities will Dr. Evan Thomas have at Adia Med (ADIA)?
What is the status of Adia Med's AHSCT program mentioned by ADIA?
What relevant clinical experience does Dr. Evan Thomas bring to Adia Med (ADIA)?
How can clinic owners or healthcare practitioners contact ADIA about licensing or partnerships?
